Stanniocalcin-1, a novel anti-inflammatory protein

Stanniocalcin-1,一种新型抗炎蛋白

基本信息

  • 批准号:
    8515390
  • 负责人:
  • 金额:
    $ 31.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2015-07-31
  • 项目状态:
    已结题

项目摘要

Macrophages are important mediators of inflammation. Our data show stanniocalcin-1 (STC1) decreases macrophage response to chemoattractants and migration across an endothelial monolayer. STC1 also diminishes superoxide generation in macrophages, by inducing uncoupling protein-2 (UCP2), and inhibits the NF-¿B pathway. In cultured endothelial cells, STC1 inhibits cytokine-induced changes in permeability and tight junction protein expression. STC1 transgenic mice, which exhibit elevated serum levels and preferential expression of STC1 in macrophages and endothelium, display less inflammatory macrophages in the glomeruli during anti-glomerular basement membrane (GBM) disease, resulting in kidney protection. Overall hypothesis: STC1 suppresses inflammation through inhibition of macrophage recruitment and function, and cytokine-induced increase in endothelial permeability. In Specific Aim I, we will determine mechanisms of UCP2 upregulation by STC1 and the role of superoxide in STC1-mediated inhibition of NF-¿B in macrophages. In Specific Aim II, we will determine the effect of STC1 on cytokine-induced changes in expression and assembly of tight junction proteins in cultured primary kidney endothelial cells. In Specific Aim III, in the context of anti-GBM disease, we will examine endothelial permeability of native kidney vessels, as well as kidney inflammation and function, after kidney endothelium-specific or macrophage-specific overexpression or deletion of STC1.
巨噬细胞是炎症的重要介质。我们的数据显示,锡钙素-1(STC1)减少 巨噬细胞对趋化物质的反应和跨越内皮单分子层的迁移。STc1也 通过诱导解偶联蛋白-2(UCP2)减少巨噬细胞中超氧化物的产生,并抑制 核因子-B途径。在培养的内皮细胞中,STC1抑制细胞因子诱导的通透性和紧张性变化 连接蛋白的表达。STC1转基因小鼠,表现出较高的血清水平和优先 STC1在巨噬细胞和内皮细胞中的表达,显示肾小球中炎症较轻的巨噬细胞 在抗肾小球基底膜(GBM)疾病期间,导致肾脏保护。总括 假设:STC1通过抑制巨噬细胞募集和功能来抑制炎症,并且 细胞因子诱导的内皮通透性增加。在具体目标一中,我们将确定 STc1上调UCP2表达及超氧化物在STc1抑制巨噬细胞核因子-βB中的作用 在特定的目标II中,我们将确定STC1在细胞因子诱导的表达变化和 在原代培养的肾内皮细胞中组装紧密连接蛋白。在具体目标三中,在 在抗GBM疾病的背景下,我们将检测自体肾血管的内皮通透性,以及 肾内皮细胞特异性或巨噬细胞特异性过度表达后的肾脏炎症和功能 或STc1的删除。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID SHEIKH-HAMAD其他文献

DAVID SHEIKH-HAMAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID SHEIKH-HAMAD', 18)}}的其他基金

Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    8824828
  • 财政年份:
    2014
  • 资助金额:
    $ 31.58万
  • 项目类别:
Megalin, mitochondrial intracrine signaling and the kidney
巨蛋白、线粒体内分泌信号传导和肾脏
  • 批准号:
    10427148
  • 财政年份:
    2014
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    8633244
  • 财政年份:
    2014
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    9339510
  • 财政年份:
    2014
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7899903
  • 财政年份:
    2009
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8131592
  • 财政年份:
    2009
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8320393
  • 财政年份:
    2009
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7729602
  • 财政年份:
    2009
  • 资助金额:
    $ 31.58万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7687670
  • 财政年份:
    2009
  • 资助金额:
    $ 31.58万
  • 项目类别:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
NIH 校内 NRSA 机构培训计划
  • 批准号:
    2213315
  • 财政年份:
    1993
  • 资助金额:
    $ 31.58万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 31.58万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了